Advanced Stage Prostate Cancer Treatment using JNJ-80038114

Study Description

This study aims to identify the appropriate phase 2 dose(s) of JNJ-80038114 for advanced stage prostate cancer and evaluate its safety during dose escalation and expansion.

Study Details

Registry ID:

NCT05441501

Conditions:

Prostatic Neoplasms

Phase:

Phase 1

Target Enrollment:

39 participants

Start Date:

November 15, 2022

Age Range:

18–999 years

Gender:

Male

Healthy Volunteers:

No

Study Locations (10 sites)

• Universitatsklinikum Freiburg
  FreiburgGermany, Germany
• Royal Marsden Hospital
  SuttonUnited Kingdom, United Kingdom
• University College London Hospitals NHSFT
  LondonUnited Kingdom, United Kingdom
• The Christie NHS Foundation Trust - Christie Hospital
  ManchesterUnited Kingdom, United Kingdom
• The Christie NHS Foundation Trust - Christie Hospital
  Manchester, Greater ManchesterUnited Kingdom, United Kingdom
• The Christie NHS Foundation Trust Christie Hospital
  ManchesterUnited Kingdom, United Kingdom
• Sidney Kimmel Cancer Center - Jefferson Health
  Philadelphia, PennsylvaniaUnited States, United States
• Center for Cancer Research National Cancer Institute
  Bethesda, MarylandUnited States, United States
• Sarah Cannon Research Institute
  Nashville, TennesseeUnited States, United States
• University Of Minnesota
  Minneapolis, MinnesotaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →